Literature DB >> 15680278

Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats.

Hui-Ching Lin1, Fang-Jung Wan, Chin-Chen Wu, Che-Se Tung, Tzuei-Hsia Wu.   

Abstract

Free radicals and proinflammatory mediators have been implicated in the pathogenesis of endotoxic shock, a disease with high mortality caused by Gram-negative bacterial endotoxin. Hyperbaric oxygen is used as an adjuvant therapy for various inflammatory diseases and shows beneficial effects in lipopolysaccharide-induced shock syndrome. However, the underlying mechanisms for these effects are still to be defined. In this study, we investigated the effect of hyperbaric oxygen on inflammatory mediators, free radicals, and mortality in endotoxic rats. Wistar-Kyoto rats were injected with lipopolysaccharide (10 mg/kg) and then exposed to aminoguanidine, an inhibitor of inducible nitric oxide (NO) synthase (bolus injection 2 h after lipopolysaccharide), or hyperbaric oxygen (2 ATA for 60 min 1, 4, 9, and 24 h after lipopolysaccharide). Plasma tumor necrosis factor alpha (TNF-alpha), NO, and superoxide anion were detected and the vasorelaxation response and survival rate were assessed. The results demonstrated that increases in plasma TNF-alpha and NO, and the vasohyporeactivity induced by lipopolysaccharide treatment were significantly inhibited by hyperbaric oxygen and aminoguanidine. Mortality and vascular superoxide anion production of lipopolysaccharide treatment were also markedly reduced by hyperbaric oxygen treatment, but were not restored by aminoguanidine. None of the parameters was changed by hyperbaric oxygen treatment alone. Thus, repeated hyperbaric oxygen exposure significantly attenuated the inflammatory mediators, free radicals, and mortality in endotoxic rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15680278     DOI: 10.1016/j.ejphar.2004.12.021

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Brief report: Hyperbaric oxygen therapy (HBOT) in children with autism spectrum disorder: a clinical trial.

Authors:  Stephen Bent; Kiah Bertoglio; Paul Ashwood; Edward Nemeth; Robert L Hendren
Journal:  J Autism Dev Disord       Date:  2012-06

Review 2.  Subcellular Energetics and Metabolism: Potential Therapeutic Applications.

Authors:  Robert H Thiele
Journal:  Anesth Analg       Date:  2017-06       Impact factor: 5.108

3.  Early hyperbaric oxygen therapy improves survival in a model of severe sepsis.

Authors:  Jonathan L Halbach; James M Prieto; Andrew W Wang; Dennis Hawisher; David M Cauvi; Tony Reyes; Jonathan Okerblom; Israel Ramirez-Sanchez; Francisco Villarreal; Hemal H Patel; Stephen W Bickler; George A Perdrizet; Antonio De Maio
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-05-15       Impact factor: 3.619

4.  Combination of allopurinol and hyperbaric oxygen therapy: a new treatment in experimental acute necrotizing pancreatitis?

Authors:  Bilgin Comert; Ahmet Turan Isik; Sezai Aydin; Ergun Bozoglu; Bulent Unal; Salih Deveci; Nuket Mas; Esref Cinar; Mehmet Refik Mas
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

5.  Hyperbaric oxygenation reduces overexpression of c-Fos and oxidative stress in the brain stem of experimental endotoxemic rats.

Authors:  Hui-Ching Lin; Fang-Jung Wan
Journal:  Intensive Care Med       Date:  2008-01-12       Impact factor: 17.440

6.  The effect of iNOS inhibitors and hyperbaric oxygen treatment in a rat model of experimental colitis.

Authors:  Cemal Nuri Ercin; Zeki Yesilova; Ahmet Korkmaz; Ayhan Ozcan; Cagatay Oktenli; Ahmet Uygun
Journal:  Dig Dis Sci       Date:  2008-10-30       Impact factor: 3.199

7.  Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation-the protocol of the prospective cohort BIONEC study.

Authors:  Marco Bo Hansen; Ulf Simonsen; Peter Garred; Ole Hyldegaard
Journal:  BMJ Open       Date:  2015-05-11       Impact factor: 2.692

8.  Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?

Authors:  Anders Kjellberg; Antonio De Maio; Peter Lindholm
Journal:  Med Hypotheses       Date:  2020-08-30       Impact factor: 1.538

9.  How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark.

Authors:  Peter Polzik; Pär I Johansson; Ole Hyldegaard
Journal:  BMJ Open       Date:  2017-10-05       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.